靜脈內平滑肌瘤伴隨心臟侵犯

Intravenous Leiomyomatosis with Cardiac Extension

10.6320/FJM.202203_26(2).0005

趙書平(Shu-Ping Chao)；呂明仁(Ming-Jen Lu)

心臟腫瘤 ； 靜脈內平滑肌瘤 ； cardiac tumor ； intravenous leiomyomatosis

台灣醫學

26卷2期（2022 / 03 / 25）

166 - 169

繁體中文

靜脈內平滑肌瘤是相當罕見的良性腫瘤，可能源自於子宮肌瘤或子宮內的血管壁，其發展緩慢，但可能經由下腔靜脈侵入右心，導致心臟衰竭、昏厥、甚至猝死。正因其罕見，所以可能會被誤診成其他疾病。此個案報告中，我們報告了一位51歲有子宮肌瘤病史的女性，因體檢意外發現右心房腫瘤，初始診斷為黏液瘤。於手術中發現腫瘤是由下腔靜脈侵入到右心房，電腦斷層顯示，高血管性的腫瘤從子宮經由右側卵巢靜脈，上行至下腔靜脈。病理組織學的最終報告為靜脈內平滑肌瘤。此個案報告顯示，當發現右心腫瘤時，需詳細的詢問病史，並仔細的檢查下腔靜脈。有子宮肌瘤病史的中年女性合併右心腫瘤，需考慮靜脈內平滑肌瘤的可能性。

Intravenous leiomyomatosis is a rare benign tumor with slow growth. Smooth muscle tumors may originate from either a uterine myoma or from the wall of a uterine vessel. Intravenous leiomyomatosis may grow in the inferior vena cava and extend into right heart in rare cases, leading to heart failure, syncope and sudden death. Due to its rarity, misdiagnosis is common. In this case report, we describe a 51-year-old woman with a history of uterine myoma. A right atrial tumor was found unexpectedly during echocardiography when undergoing routine health examination. Our first diagnosis was myxoma. However, the tumor was found extending from the inferior vena cava during surgical intervention. The computed tomography showed a hypervascular tumor, originated from the uterine, extended from the right ovarian vein to the suprarenal inferior vena cava. The final pathohistological report was intravenous leiomyomatosis. The present case report illustrated a thorough history taking and a careful examination of the inferior vena cava are necessary when finding a right heart tumor on echocardiography. Intravenous leiomyomatosis must be considered if finding a right heart tumor in a middle-aged woman with a history of uterine myoma.

1. Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938-56.
   連結：
2. Chiu WY, Yang WS, Chien JY, et al. The influence of alendronate and tooth extraction on the incidence of osteonecrosis of the jaw among osteoporotic subjects. PLOS One 2018;13:e0196419.
   連結：
3. Vahtsevanos K, Kyrgidis A, Verrou E, et al. Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw. J Clin Oncol 2009;27:5356-62.
   連結：
4. Vescovi P, Campisi G, Fusco V, et al. Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Italian multicenter study. Oral Oncol 2011;47:191-4.
   連結：
5. Saad F, Brown JE, Van Poznak C, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann Oncol 2012;23:1341-7.
   連結：
6. Scully C, Madrid C, Bagan J. Dental endosseous implants in patients on bisphosphonate therapy. Implant Dent 2006;15:212-8.
   連結：
7. Grant BT, Amenedo C, Freeman K, et al. Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases. J Oral Maxillofac Surg 2008;66:223-30.
   連結：
8. Bell BM, Bell RE. Oral bisphosphonates and dental implants: a retrospective study. J Oral Maxillofac Surg 2008;66:1022-4.
   連結：
9. Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res 2009;20(Suppl 4):87-95.
   連結：
10. Javed F, Almas K. Osseointegration of dental implants in patients undergoing bisphosphonate treatment: a literature review. J Periodontol 2010;81:479-84.
    連結：
11. Vohra F, Al-Rifaiy MO, Almas K, et al. Efficacy of systemic bisphosphonate delivery on osseointegration of implants under osteoporotic conditions: Lessons from animal studies. Arch Oral Biol 2014;59:912-20.
    連結：
12. Holzinger D, Seemann R, Matoni N, et al. Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2014;72:1937.
    連結：
13. Tallarico M, Canullo L, Xhanari E, et al. Dental implants treatment outcomes in patient under active therapy with alendronate: 3‐year follow‐up results of a multicenter prospective observational study. Clin Oral Implants Res 2016:27:943-9.
    連結：
14. Ata-Ali J, Ata-Ali F, Penarrocha-Oltra D, et al. What is the impact of bisphosphonate therapy upon dental implant survival? A systematic review and meta-analysis. Clin Oral Implants Res 2016:27:e38-e46
    連結：
15. Walter C, Al-Nawas B, Tim W, et al. Dental implants in patients treated with antiresorptive medication – A systematic literature review. Int J Implant Dent 2016;2:9-24.
    連結：
16. de-Freitas NR, Lima LB, de-Moura MB, et al. Bisphosphonate treatment and dental implants: A systematic review. Med Oral Patol Oral Cir Bucal. 2016;21:e644-51.
    連結：
17. Guazzo R, Sbricoli L, Ricci S, et al. Medication-related osteonecrosis of the jaw and dental implants failures: A systematic review. J Oral Implantol 2017;43:51-7.
    連結：
18. Kellesarian SV, Abduljabbar T, Vohra F, et al. Role of local alendronate delivery on the osseointegration of implants: a systematic review and meta-analysis. Int J Oral Maxillofac Surg 2017; 46: 912-21.
    連結：
19. Goss A, Bartold M, Sambrook P, et al. The nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in dental implant patients: A South Australian case series. J Oral Maxillofac Surg 2010;68:337-43.
    連結：
20. Fugazzotto PA, Lightfoot WS, Jaffin R, et al. Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow‐up, and the incidence of complications in two private practices. J Periodontol 2007;78:1664-9.
    連結：
21. Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaw associated with dental implants. J Oral Maxillofac Surg 2010;68:790-6.
    連結：
22. Jacobsen C, Metzler P, Rossle M, et al. Osteopathology induced by bisphosphonates and dental implants: clinical observations. Clin Oral Investig 2013;17:167-75.
    連結：
23. Kwon TG, Lee CO, Park JW, et al. Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment. Clin Oral Implants Res 2014;25:632-40.
    連結：
24. Giovannacci I, Meleti M, Manfredi M, et al. Medication-related osteonecrosis of the jaw around dental implants: implant surgery-triggered or implant presence-triggered osteonecrosis? J Craniofac Surg 2016;27: 697-701.
    連結：
25. Lopez-Cedrun JL, Sanroman JF, Garcia A, et al. Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series. Br J Oral Maxillofac Surg 2013;51:874-9.
    連結：
26. Tsao C, Darby I, Ebeling PR, et al. Oral health risk factors for bisphosphonate-associated jaw osteonecrosis. J Oral Maxillofac Surg 2013;71:1360-6.
    連結：
27. Shibahara T. Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): A twist of fate in the bone. Tohoku J Exp Med 2019;247:75-86.
    連結：
28. Berglundh T, Zitzmann NU, Donati M. Are peri-implantitis lesions different from periodontitis lesions? J Clin Periodontol 2011;38(Suppl) 11:188-202.
    連結：
29. Fernandez Ayora A, Herion F, Rompen E, et al. Dramatic osteonecrosis of the jaw associated with oral bisphosphonates, periodontitis, and dental implant removal. J Clin Periodontol 2015;42:190-5.
    連結：
30. Marin-Fernandez AB, Garcia Medina B, Aguilar-Salvatierra A, et al. Jaw osteonecrosis management around a dental implant inserted 2 years before starting treatment with zoledronic acid. J Clin Exp Dent 2015;7:e444-6.
    連結：
31. Yamazaki T, Yamori M, Ishizaki T, et al. Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: a cohort study. Int J Oral Maxillofac Surg 2012;41:1397-403.
    連結：
32. Pogrel MA, Ruggiero SL. Previously successful dental implants can fail when patients commence anti-resorptive therapy-a case series. Int J Oral Maxillofac Surg 2018;47:220-2.
    連結：
33. Otto S, Baumann S, Ehrenfeld M, et al. Successful surgical management of osteonecrosis of the jaw due to RANK-ligand inhibitor treatment using fluorescence guided bone resection. J Craniomaxillofac Surg 2013;41:694-8.
    連結：
34. Narai S, Nagahata S. Effects of alendronate on the removal torque of implants in rats with induced osteoporosis. Int J Oral Maxillofac Implants 2003;18:218-23.
35. Jeffcoat MK. Safety of oral bisphosphonates: controlled studies on alveolar bone. Int J Oral Maxillofac Implants 2006;21:349-53.
36. Hartshorne J. Is oral bisphosphonate therapy a risk factor for implant failure? Int Dent (African ed.) 2014;5:32-6.
37. Starck WJ, Epker BN. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis: a case report. Int J Oral Maxillofac Implants 1995;10:74-8.